News for RTRX Stock

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc. Retrophin Completes Acquisition of Orphan Technologies Retrophin to Present at Upcoming Investor Conferences Retrophin Reports Third Quarter 2020 Financial Results Retrophin Announces Agreement to Acquire Orphan Technologies Retrophin to Report Third Quarter 2020 Financial Results Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Retrophin Announces Proposed Public Offering of Common Stock Retrophin Reports First Quarter 2020 Financial Results Retrophin to Present at Upcoming Investor Conferences Retrophin to Report Second Quarter 2020 Financial Results Retrophin Announces Pricing of Public Offering of Common Stock Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference Retrophin to Report First Quarter 2020 Financial Results Retrophin Reports Second Quarter 2020 Financial Results Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference